Heparin and tranexamic Acid therapy may be effective in treatment-resistant chronic urticaria with elevated d-dimer: a pilot study

Int Arch Allergy Immunol. 2010;152(4):384-9. doi: 10.1159/000292947. Epub 2010 Mar 4.

Abstract

Background: Chronic urticaria (CU) patients often present activation of the coagulation cascade and fibrinolysis whose markers correlate with disease severity.

Aim: We evaluated whether CU patients with elevated plasma D-dimer have a poor response to antihistamines, and anticoagulation and inhibition of fibrinolysis may be beneficial in these patients.

Methods: Sixty-eight consecutive patients with CU were prescribed cetirizine 10 mg daily for 2 weeks; plasma D-dimer was measured. Non-responders were given cetirizine 30 mg daily for 1 week and subsequently, in case of failure, systemic steroids. Patients with persistent uncontrolled CU and elevated D-dimer plasma levels were offered subcutaneous nadroparin 11,400 IU once a day and oral tranexamic acid 1 g three times a day for 2 weeks.

Results: D-dimer levels were elevated in 14/68 (20.6%) patients (range 306-7,317 ng/ml; normal values <278 ng/ml) and were associated with a more severe disease. Twelve of 14 patients with elevated D-dimer levels did not respond to antihistamine treatment (p = 0.0001). On the whole, 14 patients reported a poor or absent response to cetirizine 10 mg daily and only 1 of these responded satisfactorily to cetirizine 30 mg daily. Eight patients with elevated D-dimer and whose disease was not satisfactorily controlled by prednisone received nadroparin and tranexamic acid. A marked improvement of symptoms was observed in 5/8 cases.

Conclusion: Our findings indicate that CU patients with elevated D-dimer often present a more severe disease with reduced response to antihistamines. Based on this short pilot study, some of these patients may benefit from treatment with nadroparin and tranexamic acid.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Anticoagulants / administration & dosage*
  • Anticoagulants / adverse effects
  • Antifibrinolytic Agents / administration & dosage*
  • Antifibrinolytic Agents / adverse effects
  • Cetirizine / administration & dosage
  • Cetirizine / adverse effects
  • Chronic Disease
  • Disease Progression
  • Drug Resistance
  • Female
  • Fibrin Fibrinogen Degradation Products / metabolism
  • Histamine H1 Antagonists, Non-Sedating / administration & dosage
  • Histamine H1 Antagonists, Non-Sedating / adverse effects
  • Humans
  • Male
  • Middle Aged
  • Nadroparin / administration & dosage*
  • Nadroparin / adverse effects
  • Pilot Projects
  • Tranexamic Acid / administration & dosage*
  • Tranexamic Acid / adverse effects
  • Treatment Failure
  • Urticaria / diagnosis
  • Urticaria / drug therapy*
  • Urticaria / physiopathology
  • Young Adult

Substances

  • Anticoagulants
  • Antifibrinolytic Agents
  • Fibrin Fibrinogen Degradation Products
  • Histamine H1 Antagonists, Non-Sedating
  • Nadroparin
  • fibrin fragment D
  • Tranexamic Acid
  • Cetirizine